Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Capecitabine and Bevacizumab in MSS Metastatic Colorectal Cancer
NCT03396926Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2018
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in colorectal cancer (CRC), sponsored by University of California, San Francisco. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03396926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396926.